Core Insights - QuidelOrtho's shares fell 12.8% after disappointing Q3 financial results and a reduced full-year earnings forecast [1] - The company's Q3 revenue was $699.9 million, a 3.7% decrease year-over-year, despite adjusted earnings per share of $0.80 beating Wall Street expectations [1] - A significant GAAP net loss, including a non-cash goodwill impairment charge, raised investor concerns [1] - QuidelOrtho lowered its adjusted earnings per share guidance for the full year by 10.6% at the midpoint [1] Market Reaction - QuidelOrtho's shares have shown extreme volatility, with 35 moves greater than 5% in the past year, indicating significant market impact from recent news [3] - The previous notable stock movement occurred 17 days prior, when shares gained 5.5% following positive news regarding the company's commitment to transfusion medicine and FDA approval of a new product [4] Stock Performance - Since the beginning of the year, QuidelOrtho's stock has declined by 47.9%, currently trading at $23.47, which is 50.7% below its 52-week high of $47.61 [5] - An investment of $1,000 in QuidelOrtho shares five years ago would now be worth $82.80 [5]

Core Insights - QuidelOrtho Corporation showcases its leadership in transfusion medicine with the FDA approval of the MTS DAT Card and the expansion of its immunohematology portfolio at the AABB 2025 Annual Meeting [1][2][3] Product Highlights - The MTS DAT Card completes the gel-based solution for direct antiglobulin testing, enhancing laboratory efficiency and reliability when paired with the ORTHO VISION Platform [2][3] - The ORTHO VISION Max Swift Analyzer is designed for high-throughput labs, offering speed, reliability, and automation with increased sample and reagent capacity [7] - The ORTHO CONNECT Lab Management Software streamlines operations and addresses staffing challenges in laboratory networks [7] Educational Contributions - QuidelOrtho's participation in the AABB Annual Meeting includes sessions on Rh(D) antigen identification, gel test typing for DARA patients, and advanced immunohematology techniques for complex serological cases [3][7]